Pulmonary Hypertension in β‐Thalassemia
- 1 November 2005
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1054 (1) , 342-349
Abstract
Abstract: Cardiac involvement represents the leading cause of mortality in both forms of β‐thalassemia, namely, thalassemia major (TM) and thalassemia intermedia (TI), and pulmonary hypertension (PHT) is part of the cardiopulmonary complications of the disease. PHT was initially documented in a small group of TI patients with right heart failure. In a subsequent study of a large 110‐patient series, aged 32.5 ± 11.4 years, age‐related PHT was encountered in nearly 60% of cases, having caused right heart failure in six of them; interestingly, all patients had preserved left ventricular systolic function. Conflicted evidence, however, existed with respect to the development of PHT in heterogeneously treated and young TM populations. To resolve this discrepancy, a recent study compared cardiac disease between two large aged‐matched groups of TM (n= 131) and TI (n= 74) patients, both treated uniformly in the currently accepted manner (regular transfusion and chelation therapy in TM, absence of any particular treatment in TI); well‐treated TM patients, in contrast to TI patients, did not develop PHT, while systolic left ventricular dysfunction was present only in TM cases. PHT in β‐thalassemia results from a rather complex pathophysiology, in which chronic tissue hypoxia seems to hold a key role. Although both forms of the disease share a common molecular background, the diverse severity of the genetic defect and of the resulting clinical phenotype require a different therapeutic approach. Regular lifelong therapy in TM patients eliminates chronic hypoxia, thereby preventing PHT, whereas the absence of systematic treatment in TI leads to a cascade of reactions that compensate for chronic anemia, but at the same time allow the development of PHT.Keywords
This publication has 31 references indexed in Scilit:
- Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell DiseaseNew England Journal of Medicine, 2004
- Pulmonary Hypertension in Sickle Cell DiseaseNew England Journal of Medicine, 2004
- ThalassemiaHematology-American Society Hematology Education Program, 2004
- Unstable angina associated with coronary arterial calcification in a thalassemia intermedia patient with a pseudoxanthoma elasticum‐like syndromeEuropean Journal of Haematology, 2003
- Arterial Stiffness and Endothelial Function in Patients With β-Thalassemia MajorCirculation, 2002
- Elastic tissue abnormalities resembling pseudoxanthoma elasticum in β thalassemia and the sickling syndromesBlood, 2002
- Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia majorThorax, 2001
- Survival and Disease Complications in Thalassemia MajorAnnals of the New York Academy of Sciences, 1998
- Low plasma heparin cofactor II levels in thalassaemia syndromes are corrected by chronic blood transfusionBritish Journal of Haematology, 1995
- Pulmonary function abnormalities in homozygous β-thalassemiaThe Journal of Pediatrics, 1986